| Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma N Bown, S Cotterill, M Łastowska, S O'Neill, ADJ Pearson, D Plantaz, ... New England Journal of Medicine 340 (25), 1954-1961, 1999 | 667 | 1999 |
| Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma T Otto, S Horn, M Brockmann, U Eilers, L Schüttrumpf, N Popov, ... Cancer cell 15 (1), 67-78, 2009 | 620 | 2009 |
| Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? A Zoubek, B Dockhorn-Dworniczak, O Delattre, H Christiansen, F Niggli, ... Journal of clinical oncology 14 (4), 1245-1251, 1996 | 341 | 1996 |
| MYCN regulates oncogenic MicroRNAs in neuroblastoma JH Schulte, S Horn, T Otto, B Samans, LC Heukamp, UC Eilers, M Krause, ... International journal of cancer 122 (3), 699-704, 2008 | 306 | 2008 |
| Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma H Christiansen, F Lampert British journal of cancer 57 (1), 121-126, 1988 | 201 | 1988 |
| Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma J Vandesompele, M Baudis, K De Preter, N Van Roy, P Ambros, N Bown, ... Journal of Clinical Oncology 23 (10), 2280-2299, 2005 | 198 | 2005 |
| BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas K Nowak, K Kerl, D Fehr, C Kramps, C Gessner, K Killmer, B Samans, ... Nucleic acids research 34 (6), 1745-1754, 2006 | 164 | 2006 |
| Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma B Berwanger, O Hartmann, E Bergmann, S Bernard, D Nielsen, M Krause, ... Cancer cell 2 (5), 377-386, 2002 | 163 | 2002 |
| Prognostic impact of gene expression–based classification for neuroblastoma A Oberthuer, B Hero, F Berthold, D Juraeva, A Faldum, Y Kahlert, ... Journal of Clinical Oncology 28 (21), 3506-3515, 2010 | 142 | 2010 |
| Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen … C Poremba, C Scheel, B Hero, H Christiansen, KL Schaefer, J Nakayama, ... Journal of clinical oncology 18 (13), 2582-2592, 2000 | 134 | 2000 |
| Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling A Schramm, JH Schulte, L Klein-Hitpass, W Havers, H Sieverts, ... Oncogene 24 (53), 7902-7912, 2005 | 132 | 2005 |
| Comparative genomic hybridization (CGH) analysis of neuroblastomas—an important methodological approach in paediatric tumour pathology C BRINKSCHMIDT, H CHRISTIANSEN, HJ TERPE, R SIMON, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 1997 | 132 | 1997 |
| Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation A Weber, J Marquardt, D Elzi, N Forster, S Starke, A Glaum, D Yamada, ... The EMBO journal 27 (11), 1563-1574, 2008 | 122 | 2008 |
| Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? J Vandesompele, F Speleman, N Van Roy, G Laureys, C Brinkschmidt, ... Medical and Pediatric Oncology: The Official Journal of SIOP—International …, 2001 | 109 | 2001 |
| Telomerase activity distinguishes between neuroblastomas with poor prognosis C Poremba, H Willenbring, B Hero, H Christiansen, KL Schäfer, ... Annals of oncology 10 (6), 715-721, 1999 | 90 | 1999 |
| Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas C Brinkschmidt, C Poremba, H Christiansen, R Simon, KL Schäfer, ... British journal of cancer 77 (12), 2223-2229, 1998 | 84 | 1998 |
| The current contribution of molecular factors to risk estimation in neuroblastoma patients F Berthold, K Şahin, B Hero, H Christiansen, M Gehring, D Harms, S Horz, ... European Journal of Cancer 33 (12), 2092-2097, 1997 | 81 | 1997 |
| Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma H Christiansen, K Sahin, F Berthold, B Hero, HJ Terpe, F Lampert European Journal of Cancer 31 (4), 541-544, 1995 | 74 | 1995 |
| Heterogeneity of the MYCN oncogene in neuroblastoma J Theissen, M Boensch, R Spitz, D Betts, S Stegmaier, H Christiansen, ... Clinical Cancer Research 15 (6), 2085-2090, 2009 | 71 | 2009 |
| Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma E Berger, R Soldati, N Huebener, O Hohn, A Stermann, T Durmus, ... Cancer letters 331 (2), 167-173, 2013 | 66 | 2013 |
Jo Vandesompeleprofessor in functional cancer genomics and applied bioinformaticsVerified email at ugent.be
